Voyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC boosted its stake in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 0.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,079,509 shares of the company’s stock after purchasing an additional 6,740 shares during the period. Geode Capital Management LLC owned approximately 1.98% of Voyager Therapeutics worth $6,316,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in VYGR. Great Point Partners LLC acquired a new position in shares of Voyager Therapeutics during the 2nd quarter valued at $12,668,000. Erste Asset Management GmbH acquired a new position in shares of Voyager Therapeutics during the third quarter worth about $6,192,000. Armistice Capital LLC boosted its position in shares of Voyager Therapeutics by 11.3% in the second quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $41,132,000 after buying an additional 528,000 shares during the period. American Century Companies Inc. grew its stake in shares of Voyager Therapeutics by 32.4% in the second quarter. American Century Companies Inc. now owns 1,019,332 shares of the company’s stock valued at $8,063,000 after buying an additional 249,659 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in shares of Voyager Therapeutics by 17.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 294,420 shares of the company’s stock valued at $2,329,000 after buying an additional 44,289 shares during the period. Institutional investors and hedge funds own 48.03% of the company’s stock.

Insider Activity at Voyager Therapeutics

In other news, COO Robin Swartz sold 6,500 shares of the stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the sale, the chief operating officer now directly owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. This represents a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.53% of the stock is currently owned by company insiders.

Voyager Therapeutics Stock Performance

Shares of NASDAQ:VYGR opened at $6.04 on Friday. The firm has a 50 day simple moving average of $6.21 and a 200 day simple moving average of $6.90. Voyager Therapeutics, Inc. has a 52 week low of $5.19 and a 52 week high of $11.44. The company has a market cap of $329.94 million, a PE ratio of 8.51 and a beta of 0.90.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.29. The business had revenue of $24.63 million during the quarter, compared to analysts’ expectations of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same period last year, the company posted ($0.59) earnings per share. On average, equities analysts predict that Voyager Therapeutics, Inc. will post -0.89 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on VYGR shares. Citigroup began coverage on shares of Voyager Therapeutics in a research note on Monday, December 2nd. They set a “buy” rating and a $12.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a report on Thursday, November 14th. Leerink Partners started coverage on Voyager Therapeutics in a research note on Wednesday, October 16th. They set an “outperform” rating and a $15.00 target price for the company. Wedbush assumed coverage on Voyager Therapeutics in a research note on Friday, November 29th. They issued an “outperform” rating and a $11.00 price target on the stock. Finally, Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $17.43.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.